Obstructive sleep apnea, the NLRP3 inflammasome and the potential effects of incretin therapies
Obstructive sleep apnea (OSA) is a common sleep disorder associated with serious neurological and cardiovascular complications. Intermittent hypoxia and reoxygenation, a key feature of OSA, produces molecular signals that activate various inflammatory pathways, notably the inflammasome—a multiprotei...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Sleep |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/frsle.2024.1524593/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841555094718382080 |
|---|---|
| author | Michelle Wei Jennifer A. Teske Jennifer A. Teske Saif Mashaqi Saif Mashaqi Daniel Combs Daniel Combs Daniel Combs |
| author_facet | Michelle Wei Jennifer A. Teske Jennifer A. Teske Saif Mashaqi Saif Mashaqi Daniel Combs Daniel Combs Daniel Combs |
| author_sort | Michelle Wei |
| collection | DOAJ |
| description | Obstructive sleep apnea (OSA) is a common sleep disorder associated with serious neurological and cardiovascular complications. Intermittent hypoxia and reoxygenation, a key feature of OSA, produces molecular signals that activate various inflammatory pathways, notably the inflammasome—a multiprotein complex that promotes the release of pro-inflammatory cytokines including IL-18 and IL-1β. This results in systemic inflammation, which contributes to the development of the neurological and cardiovascular complications seen in OSA. In this review, we will first examine the pathways through which intermittent hypoxia induces inflammasome activation. Then, we will connect the inflammasome to the downstream neurological and cardiovascular effects of OSA. Finally, we will explore potential interactions between the inflammasome and OSA treatments including Continuous Positive Airway Pressure therapy and glucagon like peptide-1 receptor agonists (GLP-1RAs). |
| format | Article |
| id | doaj-art-75a51fb91f5d442489df9f436b167ab5 |
| institution | Kabale University |
| issn | 2813-2890 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Sleep |
| spelling | doaj-art-75a51fb91f5d442489df9f436b167ab52025-01-08T06:12:20ZengFrontiers Media S.A.Frontiers in Sleep2813-28902025-01-01310.3389/frsle.2024.15245931524593Obstructive sleep apnea, the NLRP3 inflammasome and the potential effects of incretin therapiesMichelle Wei0Jennifer A. Teske1Jennifer A. Teske2Saif Mashaqi3Saif Mashaqi4Daniel Combs5Daniel Combs6Daniel Combs7University of Arizona Health Sciences Center for Sleep and Circadian Sciences, University of Arizona, Tucson, AZ, United StatesUniversity of Arizona Health Sciences Center for Sleep and Circadian Sciences, University of Arizona, Tucson, AZ, United StatesSchool of Nutritional Sciences and Wellness, University of Arizona, Tucson, AZ, United StatesUniversity of Arizona Health Sciences Center for Sleep and Circadian Sciences, University of Arizona, Tucson, AZ, United StatesDepartment of Medicine, University of Arizona, Tucson, AZ, United StatesUniversity of Arizona Health Sciences Center for Sleep and Circadian Sciences, University of Arizona, Tucson, AZ, United StatesDepartment of Medicine, University of Arizona, Tucson, AZ, United StatesDepartment of Pediatrics, University of Arizona, Tucson, AZ, United StatesObstructive sleep apnea (OSA) is a common sleep disorder associated with serious neurological and cardiovascular complications. Intermittent hypoxia and reoxygenation, a key feature of OSA, produces molecular signals that activate various inflammatory pathways, notably the inflammasome—a multiprotein complex that promotes the release of pro-inflammatory cytokines including IL-18 and IL-1β. This results in systemic inflammation, which contributes to the development of the neurological and cardiovascular complications seen in OSA. In this review, we will first examine the pathways through which intermittent hypoxia induces inflammasome activation. Then, we will connect the inflammasome to the downstream neurological and cardiovascular effects of OSA. Finally, we will explore potential interactions between the inflammasome and OSA treatments including Continuous Positive Airway Pressure therapy and glucagon like peptide-1 receptor agonists (GLP-1RAs).https://www.frontiersin.org/articles/10.3389/frsle.2024.1524593/fullobstructive sleep apneainflammasomeintermittent hypoxemiaglucagon like peptide-1 receptor agonistscontinuous positive airway pressure therapy |
| spellingShingle | Michelle Wei Jennifer A. Teske Jennifer A. Teske Saif Mashaqi Saif Mashaqi Daniel Combs Daniel Combs Daniel Combs Obstructive sleep apnea, the NLRP3 inflammasome and the potential effects of incretin therapies Frontiers in Sleep obstructive sleep apnea inflammasome intermittent hypoxemia glucagon like peptide-1 receptor agonists continuous positive airway pressure therapy |
| title | Obstructive sleep apnea, the NLRP3 inflammasome and the potential effects of incretin therapies |
| title_full | Obstructive sleep apnea, the NLRP3 inflammasome and the potential effects of incretin therapies |
| title_fullStr | Obstructive sleep apnea, the NLRP3 inflammasome and the potential effects of incretin therapies |
| title_full_unstemmed | Obstructive sleep apnea, the NLRP3 inflammasome and the potential effects of incretin therapies |
| title_short | Obstructive sleep apnea, the NLRP3 inflammasome and the potential effects of incretin therapies |
| title_sort | obstructive sleep apnea the nlrp3 inflammasome and the potential effects of incretin therapies |
| topic | obstructive sleep apnea inflammasome intermittent hypoxemia glucagon like peptide-1 receptor agonists continuous positive airway pressure therapy |
| url | https://www.frontiersin.org/articles/10.3389/frsle.2024.1524593/full |
| work_keys_str_mv | AT michellewei obstructivesleepapneathenlrp3inflammasomeandthepotentialeffectsofincretintherapies AT jenniferateske obstructivesleepapneathenlrp3inflammasomeandthepotentialeffectsofincretintherapies AT jenniferateske obstructivesleepapneathenlrp3inflammasomeandthepotentialeffectsofincretintherapies AT saifmashaqi obstructivesleepapneathenlrp3inflammasomeandthepotentialeffectsofincretintherapies AT saifmashaqi obstructivesleepapneathenlrp3inflammasomeandthepotentialeffectsofincretintherapies AT danielcombs obstructivesleepapneathenlrp3inflammasomeandthepotentialeffectsofincretintherapies AT danielcombs obstructivesleepapneathenlrp3inflammasomeandthepotentialeffectsofincretintherapies AT danielcombs obstructivesleepapneathenlrp3inflammasomeandthepotentialeffectsofincretintherapies |